Adagio will now put its resources toward completing the pivotal U.S. trial of its vCLAS catheter, and its subsequent ...

The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.65 billion ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after ...

Huntington’s disease was long thought to be caused by the slow buildup of a toxic protein, but new research has reveale | ...

Gene therapy maker bluebird bio’s 15-year flight has landed in the nest of private equity firms Carlyle and SK Capital in a ...

AbbVie-partnered Mission Therapeutics is tweaking its trajectory, closing a preclinical laboratory in the U.K. to focus on ...

Nxera Pharma has sold the Asia-Pacific rights to Idorsia's phase 3-stage autoimmune drug to Viatris for $10 million upfront.